Genitourinary Cancer News

Maintenance pembrolizumab immediately following first-line platinum-based chemotherapy prolonged PFS and led to additional objective responses among a cohort of patients with metastatic urothelial cancer, according to results of a randomized phase 2 study published in Journal of Clinical Oncology.

The FDA granted breakthrough therapy designation to avelumab for first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma.

The FDA granted fast track designation to sacituzumab govitecan for treatment of certain adults with locally advanced or metastatic urothelial cancer.

Parker Institute for Cancer Immunotherapy awarded up to $2.75 million in grant funding to six early career researchers.

The FDA granted fast track designation to IPI-549 in combination with nivolumab for the treatment of advanced urothelial cancer.

The combination of enfortumab vedotin and pembrolizumab conferred high rates of durable responses among cisplatin-ineligible patients with metastatic urothelial carcinoma, according to results of the multicohort EV-103 study.

A randomized phase 3 trial designed to evaluate two experimental first-line treatment approaches for patients with advanced bladder cancer failed to meet its primary endpoints.

All-cause and cancer-specific mortality rates have declined overall among adolescent and young adult cancer survivors during the past 4 decades, according to results of a retrospective study published in Journal of the National Cancer Institute.

De-escalation of treatment after two cycles of chemotherapy and a negative PET scan appeared safe and feasible among a cohort of men with low-volume metastatic seminoma, according to results of a phase 2 trial presented at Genitourinary Cancers Symposium.

The FDA granted breakthrough therapy designation to enfortumab vedotin-ejfv in combination with pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible for first-line cisplatin-based chemotherapy, according to a press release from the agent’s manufacturer.